(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

A total of 545 subjects with episodic or chronic migraine, who are aged 18 and above, were included in the trial.

AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

AbbVie Golden Ticket Comes to a ClosePress release2025-06-18 11:48AbbVie Golden Ticket ceremony at SmiLe Venture Hub.Lund, Sweden – The one-year AbbVie Golden Ticket program has officially concluded – ...

Despite advances, the roles of genetics and microenvironment in CLL are not fully understood, and curative treatments may hinge on a dual approach targeting both.

Analysis revealed that patients with T-cell exhausted archetype tumors had significantly higher rates of progressive disease ...

The latest report, Panic Attack Treatment Global Market Report 2025, brings light to the rapid growth of panic attack treatment market in recent years. The market size is expected to surge from $3.04 ...

The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

In its fourth year, the coveted Miss America Volunteer pageant returns to the Carl Perkins Civic Center stage with preliminary night one on June 18 ...

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...